28.00 +0.17 (0.61%)
Pre-Market: 7:28AM EDT
|Bid||26.97 x 1100|
|Ask||28.50 x 800|
|Day's Range||27.05 - 27.91|
|52 Week Range||11.65 - 36.65|
|Beta (3Y Monthly)||1.15|
|PE Ratio (TTM)||1.50|
|Earnings Date||Nov 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.88|
STAINES-UPON-THAMES, United Kingdom , Oct. 16, 2018 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Wednesday, Nov. 14, 2018 ...
STAINES-UPON-THAMES, United Kingdom, Oct. 15, 2018 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today announced that Stratatech, a Mallinckrodt company, was awarded approximately $26 million in additional Project BioShield funding by the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response. The latest award will provide support for pediatric studies related to the company's StrataGraft® viable, engineered skin tissue. Mallinckrodt is committed to developing new therapies for the pediatric population worldwide.
"We are now in the next phase of this opioid crisis, where the majority of deaths arise from fentanyl.”
-- Company Seeks Approval of New Drug Application for MNK-812 Through 505(b)2 Regulatory Pathway -- STAINES-UPON-THAMES, United Kingdom , Oct. 8, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading ...
From paramedics to soldiers, a true synthetic blood substitute could change the world of health care. At least that’s what Kalocyte’s new CEO Elaine Haynes believes.
Competition from Praxair, Inc. (NYSE: PX ) has rattled Mallinckrodt PLC (NYSE: MNK ) investors, but Jefferies' bullish thesis remains intact. The Analyst Jeffries analyst Anthony Petrone reiterated a ...
The Dow Jones Industrial Average fell 0.75 percent to close at 26,627.48, while the S&P 500 Index dropped 0.82 percent to close at 2,901.61. The Nasdaq Composite Index shed 1.81 percent to close at 7,879.51.
Given the recent spate of setbacks suffered by Mylan (MYL), we suggest investing in better-ranked generic/drug companies with favorable growth profile.
New opioid legislation, which many expect will pass Congress by the end of the year, should benefit certain behavioral health providers and drugmakers, Height Capital Markets analyst Andrea Harris said on Wednesday. Among other provisions, the legislation would allow states more federal funding for substance use disorder services over the next four years. Though which states may end up participating will depend on several factors, some of the likely contenders would provide either high or modest benefit for Acadia Healthcare Co. Inc. and/or Universal Health Services Inc. , which own behavioral health facilities, with potential areas including Colorado, Connecticut, D.C., Ohio and Missouri, Harris said. The measure, which has bipartisan and bicameral support, additionally aims to increase access to medications for opioid addiction, which could lift drugmakers like Teva Pharmaceutical Industries Ltd. , Mallinckrodt PLC and Alkermes PLC , Harris said; the legislation is also "slightly negative" for Centene , Molina and WellCare , and excludes a provision that might have helped Heron Therapeutics . The S&P 500 has risen 7.3% over the last three months and the Dow Jones Industrial Average has lifted 9.3%.
SAN FRANCISCO, Sept. 25, 2018-- Dance Biopharm Holdings Inc., a private biotechnology company focused on developing transformational healthcare solutions to treat diabetes and other serious chronic diseases, ...
STAINES-UPON-THAMES, United Kingdom, Sept. 25, 2018 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (MNK), a leading global specialty pharmaceutical company, announced today that it will report third quarter fiscal 2018 earnings results for the period ending Sept. 28, 2018, on Tuesday, Nov. 6, 2018. Callers will need to provide the Conference ID of 1560208. All callers will be required to provide the Conference ID of 1560208.
The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to learn about the link betweenRead More...
The biotech sector has seen some year-to-date strength, as reflected by the nearly 11-percent advance in the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ). The upward momentum became more pronounced ...
Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
STAINES-UPON-THAMES, United Kingdom , Sept. 4, 2018 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Tuesday, Oct. 2, 2018 , ...